{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:49:52Z","timestamp":1754153392173,"version":"3.41.2"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1111\/igc.0b013e3181b62f38","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:48:52Z","timestamp":1291384132000},"page":"1446-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Gregor","family":"Seliger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz P.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva J.","family":"Kantelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Gro\u03d0e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Georg","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Koelbl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Thomssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Joachim","family":"Schmoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181b62f38_bb0005","first-page":"340","article-title":"Chemotherapy of advanced ovarian cancer","volume":"25","author":"McGuire","year":"1998","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","article-title":"Ovarian cancer","volume":"60","author":"Colombo","year":"2006","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0025","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0030","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0035","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1996.14.9.2546","article-title":"Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease","volume":"14","author":"Bajetta","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","article-title":"Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer","volume":"21","author":"Bodurka","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0045","first-page":"439","article-title":"Capecitabine in treatment of platinum-resistant recurrent ovarian cancer","volume":"22","author":"Boehmer","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0050","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","article-title":"Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer","volume":"7","author":"Chollet","year":"1996","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","article-title":"Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer","volume":"88","author":"D\u2019Agostino","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.7-suppl_5-3","article-title":"Update on the role of topotecan in the treatment of recurrent ovarian cancer","volume":"7","author":"Herzog","year":"2002","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0070","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/gyno.2000.6089","article-title":"Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma","volume":"81","author":"Sorensen","year":"2001","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0090","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0095","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2004.08.028","article-title":"A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer","volume":"95","author":"Berkenblit","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2006.12.018","article-title":"Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial","volume":"105","author":"Kushner","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ygyno.2006.09.023","article-title":"Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer","volume":"104","author":"Strauss","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0110","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.1994.12.7.1458","article-title":"Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis","volume":"12","author":"Tomiak","year":"1994","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0115","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1023\/A:1008364327684","article-title":"Phase II study of gemcitabine in ovarian cancer","volume":"10","author":"von Minckwitz","year":"1999","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","article-title":"GemcitabineVa safety review","volume":"9","author":"Aapro","year":"1998","journal-title":"Anticancer Drugs."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00685109","article-title":"Saturation of 2\u2019,2\u2019-difluorodeoxycytidine 5\u2019-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine","volume":"27","author":"Grunewald","year":"1991","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/annonc\/mdf018","article-title":"Multicentre phase II study of oxaliplatin as a single-agent in cisplatin\/carboplatin \u00b1 taxane-pretreated ovarian cancer patients","volume":"13","author":"Dieras","year":"2002","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0135","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0140","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1023\/A:1008334215414","article-title":"Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience","volume":"10","author":"Faivre","year":"1999","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00684890","article-title":"Phase I study of oxaliplatin in patients with advanced cancer","volume":"25","author":"Extra","year":"1990","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0150","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2004.08.043","article-title":"Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma","volume":"22","author":"Leu","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0155","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1634\/theoncologist.12-8-999","article-title":"Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future","volume":"12","author":"Maki","year":"2007","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0160","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1634\/theoncologist.12-2-186","article-title":"New, expanded, and modified use of approved antineoplastic agents in ovarian cancer","volume":"12","author":"Markman","year":"2007","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0163-7258(00)00086-3","article-title":"Basis for effective combination cancer chemotherapy with antimetabolites","volume":"87","author":"Peters","year":"2000","journal-title":"Pharmacol Ther."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2004.03.021","article-title":"Promising combination therapies with gemcitabine","volume":"31","author":"Robinson","year":"2004","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0175","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00432-005-0673-0","article-title":"Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma","volume":"131","author":"Voigt","year":"2005","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0180","article-title":"Biweekly docetaxel (DOC), gemcitabine (GEM) and oxaliplatin (LOHP) in pretreated patients with solid tumors. Results of a phase I study. Proc Am Soc","volume":"19","author":"Wunderlich","year":"2000","journal-title":"Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0190","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ygyno.2004.05.050","article-title":"Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"94","author":"Micha","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0195","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdm136","article-title":"Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study","volume":"18","author":"Ferrandina","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0200","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1200\/JCO.2007.13.5251","article-title":"Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity","volume":"25","author":"Hochster","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0205","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study","volume":"16","author":"Gonzalez-Martin","year":"2005","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0210","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2007.06.005","article-title":"Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials","volume":"106","author":"Markman","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0215","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2003.08.001","article-title":"Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum","volume":"91","author":"Markman","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0225","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0230","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2006.10.006","article-title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxelVANZGOG 02-01","volume":"104","author":"Tinker","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0235","first-page":"3559","article-title":"Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer","volume":"25","author":"Polyzos","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0240","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1525-1438.2007.00763.x","article-title":"Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study","volume":"17","author":"Harnett","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0245","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2004.06.029","article-title":"Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study","volume":"95","author":"Pectasides","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0250","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2005.08.020","article-title":"Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer","volume":"100","author":"Nicoletto","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0255","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ygyno.2007.03.015","article-title":"A multicenter phase II study of 54. pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer","volume":"106","author":"Recchia","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/ijgc-00009577-200602001-00013","article-title":"A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma","volume":"16","author":"Valerio","year":"2006","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdj097","article-title":"A phase II study of a paclitaxel and 56. oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients","volume":"17","author":"Viens","year":"2006","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0270","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2005.04.7373","article-title":"Pretreatment CA-125 and risk of relapse in advanced ovarian cancer","volume":"24","author":"Markman","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0275","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","article-title":"Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?","volume":"22","author":"Gronlund","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181b62f38_bb0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000108591","article-title":"Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data","volume":"71","author":"Markman","year":"2006","journal-title":"Oncology."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181b62f38","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24028263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24028263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:08:02Z","timestamp":1753232882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24028263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1048891X24028263"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181b62f38","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181b62f38","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}